Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01

BACKGROUND: Previous large trials of trastuzumab (TZM) demonstrated improved outcomes in patients with HER2-positive early breast cancer. However, its effectiveness and safety in Japanese patients is not yet clear. Recently, new anti-HER2 agents were developed to improve treatment outcomes, but the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashiro, Hiroyasu, Iwata, Hiroji, Masuda, Norikazu, Yamamoto, Naohito, Nishimura, Reiki, Ohtani, Shoichiro, Sato, Nobuaki, Takahashi, Masato, Kamio, Takako, Yamazaki, Kosuke, Saito, Tsuyoshi, Kato, Makoto, Lee, Tecchuu, Kuroi, Katsumasa, Takano, Toshimi, Yasuno, Shinji, Morita, Satoshi, Ohno, Shinji, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297820/
https://www.ncbi.nlm.nih.gov/pubmed/32060785
http://dx.doi.org/10.1007/s12282-020-01057-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297820/
https://www.ncbi.nlm.nih.gov/pubmed/32060785
http://dx.doi.org/10.1007/s12282-020-01057-4

Ejemplares similares